Janssen Returns Phase I NASH Candidate to Arrowhead

J&J’s Janssen Pharmaceutical has given up on an RNAi therapeutic being developed for one of biotech’s hottest targets: non-alcoholic steatohepatitis (NASH).

Janssen’s development partner, Arrowhead Pharmaceuticals, announced Wednesday it had regained full rights to the candidate, ARO-PNPLA3 (formerly JNJ-75220795).